Oryzon Genomics S.A.
Symbole: 0RDB.L
LSE
1.97
EURPrix du marché aujourd'hui
-34.0078
Ratio P/E
-1.5775
Ratio PEG
123.58M
Cap MRK
- 0.00%
Rendement DIV
Oryzon Genomics S.A. (0RDB-L) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 22.8 | 32.7 | 48.4 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0.1 | 0.4 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 4.1 | 4.3 | 3 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 26.9 | 37.1 | 51.8 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.7 | 0.8 | 0.8 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0.6 | 0.7 | 0.3 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.6 | 0.7 | 0.3 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 82.9 | 70 | 62.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 84.1 | 71.5 | 63.2 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 111 | 108.6 | 115 | |||||||||||
balance-sheet.row.account-payables | 0 | 5.4 | 3.3 | 2.4 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 13 | 4.7 | 5.9 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 11.1 | 15.2 | 10.6 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 1.6 | 1.8 | 1 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 13.3 | 17.6 | 12.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.1 | 0 | 0 | |||||||||||
balance-sheet.row.total-liab | 0 | 33.3 | 27.5 | 22.2 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 3 | 3 | 3.2 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -13.1 | -9.2 | -4.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3.2 | 3.8 | 4.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 84.7 | 83.4 | 89.5 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 77.7 | 81.1 | 92.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 111 | 108.6 | 115 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | 77.7 | 81.1 | 92.8 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-debt | 0 | 24.1 | 19.9 | 16.5 | |||||||||||
balance-sheet.row.net-debt | 0 | 1.3 | -12.8 | -31.8 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -3.7 | -4.5 | -5.3 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0.2 | 0.2 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | 0.4 | 1.1 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0.3 | -0.1 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0.1 | 0.2 | ||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0.9 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | 3.7 | 2 | 0 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | -0.2 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -15.2 | -13.1 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -15.3 | -13.3 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.7 | -4.7 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -1.1 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 9.7 | 4.1 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 9.3 | 4.7 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0.4 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | -9.9 | -15.7 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 22.8 | 22.8 | 32.7 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 22.8 | 32.7 | 48.4 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | -2 | -4.1 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | -0.2 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | -2.1 | -4.3 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 16.8 | 12.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.5 | 0.8 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 16.3 | 11.2 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 5 | 22.1 | 18.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 5 | 22.6 | 19.7 | ||||||||||||
income-statement-row.row.interest-income | 0 | 1.3 | 0 | 0 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -1.1 | -0.4 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 17.2 | -1.1 | -0.2 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 17.2 | -1.1 | -0.2 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -1.1 | -0.4 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.2 | 0.2 | 0.2 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | -20.9 | -5.9 | -8 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | -3.7 | -7 | -8.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 2.5 | 2.8 | ||||||||||||
income-statement-row.row.net-income | 0 | -3.7 | -4.5 | -5.3 |
Questions fréquemment posées
Quel est le total de Oryzon Genomics S.A. (0RDB.L) de l'actif total?
Oryzon Genomics S.A. (0RDB.L) Le total des actifs est 111039575.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est N/A.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 0.983.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est 0.000.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est -0.447.
Quel est le revenu total de l'entreprise?
Le revenu total est -1.500.
Qu'est-ce que Oryzon Genomics S.A. (0RDB.L) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est -3705000.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 24113573.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 5027000.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 0.000.